Naik Rayees Ahmad, Rajpoot Roshni, Koiri Raj Kumar, Bhardwaj Rima, Aldairi Abdullah F, Johargy Ayman K, Faidah Hani, Babalghith Ahmad O, Hjazi Ahmed, Alsanie Walaa F, Alamri Abdulhakeem S, Alhomrani Majid, Alsharif Abdulaziz, Shkodina Anastasiia, Singh Sandeep Kumar
Biochemistry Laboratory, Department of Zoology, Dr. Harisingh Gour Vishwavidyalaya Sagar, Madhya Pradesh, 470003, India.
Department of Chemistry Poona College, Savitribai Phule Pune University, Pune 411007, India.
J Prev Alzheimers Dis. 2025 Jan;12(1):100004. doi: 10.1016/j.tjpad.2024.100004. Epub 2025 Jan 1.
Alzheimer's disease is a complicated, multifaceted, neurodegenerative illness that places an increasing strain on healthcare systems. Due to increasing malfunction and death of nerve cells, the person suffering from Alzheimer's disease (AD) slowly and steadily loses their memories, cognitive functions and even their personality. Although medications may temporarily enhance memory, there are currently no permanent therapies that can halt or cure this irreversible neurodegenerative process. Nonetheless, fast progress in comprehending the cellular and molecular abnormalities responsible for neuronal degeneration has increased confidence in the development of viable prevention and treatments. All FDA-approved anti-AD medications have merely symptomatic effects and cannot cure the illness. This necessitates the pursuit of alternate treatments. Accumulating data shows that systemic neuroinflammation, oxidative stress and associated mitochondrial dysfunction play crucial roles in the etiology of AD and precede its clinical presentation. Therefore, innovative therapeutic approaches targeting these pathophysiological components of Alzheimer's disease are being explored aggressively in the present scenario. Phytochemicals such as resveratrol, curcumin, quercetin, genistein and catechins are prospective therapies owing to their capacity to alter key AD pathogenetic pathways, such as oxidative stress, neuroinflammation, and mitochondrial dysfunction. The use of new phytochemical delivery strategies would certainly provide the possibility to solve several issues with standard anti-AD medicines. In this review, the roles of phytophenolic compound-based treatment strategies for AD are discussed.
阿尔茨海默病是一种复杂、多方面的神经退行性疾病,给医疗保健系统带来越来越大的压力。由于神经细胞功能日益失调和死亡,阿尔茨海默病患者会逐渐且持续地丧失记忆、认知功能甚至个性。尽管药物可能会暂时增强记忆力,但目前尚无能够阻止或治愈这种不可逆转的神经退行性过程的永久性疗法。然而,在理解导致神经元变性的细胞和分子异常方面取得的快速进展,增强了人们对开发可行的预防和治疗方法的信心。所有获得美国食品药品监督管理局(FDA)批准的抗阿尔茨海默病药物都仅具有对症作用,无法治愈该疾病。这就需要寻求替代治疗方法。越来越多的数据表明,全身性神经炎症、氧化应激及相关的线粒体功能障碍在阿尔茨海默病的病因中起关键作用,且早于其临床表现。因此,在当前情况下,人们正在积极探索针对阿尔茨海默病这些病理生理成分的创新治疗方法。白藜芦醇、姜黄素、槲皮素、染料木黄酮和儿茶素等植物化学物质因其能够改变关键的阿尔茨海默病致病途径,如氧化应激、神经炎症和线粒体功能障碍,而成为有前景的治疗方法。使用新的植物化学物质递送策略肯定有可能解决标准抗阿尔茨海默病药物的几个问题。在这篇综述中,讨论了基于植物酚类化合物的治疗策略对阿尔茨海默病的作用。